Halogenated 2′-benzoylpyridine thiosemicarbazone (XBpT) chelators with potent and selective anti-neoplastic activity: Relationship to intracellular redox activity

Journal of Medicinal Chemistry

Volumn 54, Issue 19, 2011, Pages 6936-6948

  Stefani, Christian ^a   Punnia Moorthy, Gaya ^a   Lovejoy, David B ^a   Jansson, Patric J ^a   Kalinowski, Danuta S ^a   Sharpe, Philip C ^b   Bernhardt, Paul V ^b   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2' BENZOYLPYRIDINE THIOSEMICARBAZONE DERIVATIVE; ANTINEOPLASTIC AGENT; CHELATING AGENT; DICHLOROFLUORESCEIN; REACTIVE OXYGEN METABOLITE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; 2',7'-DICHLOROFLUORESCEIN; ASCORBIC ACID; COORDINATION COMPOUND; FLUORESCEIN DERIVATIVE; FLUORESCENT DYE; IRON CHELATING AGENT; PYRIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CHELATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYCLIC POTENTIOMETRY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE ANALYSIS; HALOGENATION; HYDROPHILICITY; IN VITRO STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION REDUCTION POTENTIAL; STRUCTURE ACTIVITY RELATION; CELL LINE; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; ELECTROCHEMISTRY; FLUOROMETRY; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; SYNTHESIS; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; ASCORBIC ACID; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; COORDINATION COMPLEXES; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; ELECTROCHEMISTRY; FLUORESCEINS; FLUORESCENT DYES; FLUOROMETRY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IRON CHELATING AGENTS; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PYRIDINES; REACTIVE OXYGEN SPECIES; STRUCTURE-ACTIVITY RELATIONSHIP; THIOSEMICARBAZONES;

EID: 80053895153     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200924c     Document Type: Article

References (51)

1. Bergeron, R. J.; Huang, G. F.; Weimar, W. R.; Smith, R. E.; Wiegand, J.; McManis, J. S. Desferrithiocin analogue based hexacoordinate iron(III) chelators J. Med. Chem. 2003, 46, 16-24 (Pubitemid 36043783)
2. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Bussenius, J.; Smith, R. E.; Weimar, W. R. Methoxylation of desazadesferrithiocin analogues: Enhanced iron clearing efficiency J. Med. Chem. 2003, 46, 1470-1477 (Pubitemid 36512710)
3. Chua, A. C. G.; Ingram, H. A.; Raymond, K. N.; Baker, E. Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells Eur. J. Biochem. 2003, 270, 1689-1698 (Pubitemid 36532528)
4. Liu, J.; Obando, D.; Schipanski, L. G.; Groebler, L. K.; Witting, P. K.; Kalinowski, D. S.; Richardson, D. R.; Codd, R. Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload J. Med. Chem. 2010, 53, 1370-1382
5. Buss, J. L.; Torti, F. M.; Torti, S. V. The role of iron chelation in cancer therapy Curr. Med. Chem. 2003, 10, 1021-1034 (Pubitemid 36582246)
6. Torti, S. V.; Torti, F. M.; Whitman, S. P.; Brechbiel, M. W.; Park, G.; Planalp, R. P. Tumor cell cytotoxicity of a novel metal chelator Blood 1998, 92, 1384-1389 (Pubitemid 28369052)
7. Turner, J.; Koumenis, C.; Kute, T. E.; Planalp, R. P.; Brechbiel, M. W.; Beardsley, D.; Cody, B.; Brown, K. D.; Torti, F. M.; Torti, S. V. Tachpyridine, a metal chelator, induces G(2) cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation Blood 2005, 106, 3191-3199 (Pubitemid 41565918)
8. Larrick, J. W.; Cresswell, P. Modulation of cell-surface iron transferrin receptors by cellular density and state of activation J. Supramol. Struct. 1979, 11, 579-586 (Pubitemid 10067168)
9. Chaston, T. B.; Lovejoy, D. B.; Watts, R. N.; Richardson, D. R. Examination of the antiproliferative activity of iron chelators: Multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311 Clin. Cancer Res. 2003, 9, 402-414 (Pubitemid 36109758)
10. Cooper, C. E.; Lynagh, G. R.; Hoyes, K. P.; Hider, R. C.; Cammack, R.; Porter, J. B. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase J. Biol. Chem. 1996, 271, 20291-20299 (Pubitemid 26281794)
11. Nyholm, S.; Mann, G. J.; Johansson, A. G.; Bergeron, R. J.; Graslund, A.; Thelander, L. Role of ribonucleotide reductase in inhibition of mammalian-cell growth by potent iron chelators J. Biol. Chem. 1993, 268, 26200-26205 (Pubitemid 23361687)
12. Fu, D.; Richardson, D. R. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1) by iron depletion Blood 2007, 110, 752-761 (Pubitemid 47105414)
13. Le, N. T. V.; Richardson, D. R. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation Blood 2004, 104, 2967-2975 (Pubitemid 39434989)
14. Nurtjahja-Tjendraputra, E.; Fu, D.; Phang, J. M.; Richardson, D. R. Iron chelation regulates cyclin D1 expression via the proteasome: A link to iron deficiency-mediated growth suppression Blood 2007, 109, 4045-4054 (Pubitemid 46641760)
15. Yu, Y.; Kalinowski, D. S.; Kovacevic, Z.; Siafakas, A. R.; Jansson, P. J.; Stefani, C.; Lovejoy, D. B.; Sharpe, P. C.; Bernhardt, P. V.; Richardson, D. R. Thiosemicarbazones from the old to new: Iron chelators that are more than just ribonucleotide reductase inhibitors J. Med. Chem. 2009, 52, 5271-5294
16. Kalinowski, D. S.; Richardson, D. R. The evolution of iron chelators for the treatment of iron overload disease and cancer Pharmacol. Rev. 2005, 57, 547-583 (Pubitemid 43036441)
17. Barnham, K. J.; Masters, C. L.; Bush, A. I. Neurodegenerative diseases and oxidative stress Nature Rev. Drug Discovery 2004, 3, 205-214
18. Yuan, J.; Lovejoy, D. B.; Richardson, D. R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: In vitro and in vivo assessment Blood 2004, 104, 1450-1458 (Pubitemid 39166524)
19. Halliwell, B.; Gutteridge, J. M. C. Oxygen free-radicals and iron in relation to biology and medicine-Some problems and concepts Arch. Biochem. Biophys. 1986, 246, 501-514 (Pubitemid 16072574)
20. Chaston, T. B.; Watts, R. N.; Yuan, J.; Richardson, D. R. Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation Clin. Cancer Res. 2004, 10, 7365-7374 (Pubitemid 39487726)
21. Blatt, J.; Stitely, S. Antineuroblastoma activity of desferoxamine in human cell-lines Cancer Res. 1987, 47, 1749-1750 (Pubitemid 17056669)
22. Donfrancesco, A.; Deb, G.; Dominici, C.; Angioni, A.; Caniglia, M.; Desio, L.; Fidani, P.; Amici, A.; Helson, L. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECAT)-A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma Am. J. Clin. Oncol.-Cancer Clin. Trials 1992, 15, 319-322
23. Donfrancesco, A.; Deb, G.; Dominici, C.; Pileggi, D.; Castello, M. A.; Helson, L. Effects of a single course of deferoxamine in neuroblastoma patients Cancer Res. 1990, 50, 4929-4930 (Pubitemid 20257912)
24. Estrov, Z.; Tawa, A.; Wang, X. H.; Dube, I. D.; Sulh, H.; Cohen, A.; Gelfand, E. W.; Freedman, M. H. In vitro and in vivo effects of deferoxamine in neonatal acute-leukemia Blood 1987, 69, 757-761 (Pubitemid 17057452)
25. Aouad, F.; Florence, A.; Zhang, Y.; Collins, F.; Henry, C.; Ward, R. J.; Crichton, R. R. Evaluation of new iron chelators and their therapeutic potential Inorg. Chim. Acta 2002, 339, 470-480
26. Richardson, D. R. Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer Curr. Med. Chem. 2005, 12, 2711-2729 (Pubitemid 41601569)
27. Karp, J. E.; Giles, F. J.; Gojo, L.; Morris, L.; Greer, J.; Johnson, B.; Thein, M.; Sznol, M.; Low, J. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine(R)) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders Leuk. Res. 2008, 32, 71-77 (Pubitemid 350100849)
28. Ma, B.; Goh, B. C.; Tan, E. H.; Lam, K. C.; Soo, R.; Leong, S. S.; Wang, L. Z.; Mo, F.; Chan, A. T. C.; Zee, B.; Mok, T. A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine (R)) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells Invest. New Drugs 2008, 26, 169-173 (Pubitemid 351357710)
29. Mackenzie, M. J.; Saltman, D.; Hirte, H.; Low, J.; Johnson, C.; Pond, G.; Moore, M. J. A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium Invest. New Drugs 2007, 25, 553-558
30. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D. R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 14901-14906 (Pubitemid 44527826)
31. Richardson, D. R.; Sharpe, P. C.; Lovejoy, D. B.; Senaratne, D.; Kalinowski, D. S.; Islam, M.; Bernhardt, P. V. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity J. Med. Chem. 2006, 49, 6510-6521 (Pubitemid 44657445)
32. Kalinowski, D. S.; Richardson, D. R. Future of toxicology-iron chelators and differing modes of action and toxicity: The changing face of iron chelation therapy Chem. Res. Toxicol. 2007, 20, 715-720 (Pubitemid 46953677)
33. Kalinowski, D. S.; Yu, Y.; Sharpe, P. C.; Islam, M.; Liao, Y. T.; Lovejoy, D. B.; Kumar, N.; Bernhardt, P. V.; Richardson, D. R. Design, synthesis, and characterization of novel iron chelators: Structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents J. Med. Chem. 2007, 50, 3716-3729 (Pubitemid 47195478)
34. Yu, Y.; Suryo Rahmanto, Y.; Richardson, D. R. Bp44mT: An orally-active iron chelator of the thiosemicarbazone class with potent anti-tumor efficacy. Br. J. Pharmacol. 2011, June 9. DOI: 10.1111/j.1476-5381.2011.01526.x. [Epub ahead of print] PMID:21658021.
35. Bernhardt, P. V.; Caldwell, L. M.; Chaston, T. B.; Chin, P.; Richardson, D. R. Cytotoxic iron chelators: Characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues J. Biol. Inorg. Chem. 2003, 8, 866-880 (Pubitemid 37486501)
36. Richardson, D. R.; Kalinowski, D. S.; Richardson, V.; Sharpe, P. C.; Lovejoy, D. B.; Islam, M.; Bernhardt, P. V. 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: Redox activity, iron complexation and characterization of their antitumor activity J. Med. Chem. 2009, 52, 1459-1470
37. Richardson, D. R.; Tran, E. H.; Ponka, P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents Blood 1995, 86, 4295-4306
38. Ponka, P.; Richardson, D. R.; Edward, J. T.; Chubb, F. L. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilize iron from reticulocytes in vitro Can. J. Physiol. Pharmacol. 1994, 72, 659-666 (Pubitemid 24264698)
39. Richardson, D. R.; Ponka, P. The iron-metabolism of the human neuroblastoma cell-Lack of relationship between the efficacy of iron chelation and the inhibition of DNA-synthesis J. Lab. Clin. Med. 1994, 124, 660-671
40. Chaston, T. B.; Richardson, D. R. Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: Implications for toxicity in the treatment of iron overload disease J. Biol. Inorg. Chem. 2003, 8, 427-438 (Pubitemid 36578194)
41. Myhre, O.; Andersen, J. M.; Aarnes, H.; Fonnum, F. Evaluation of the probes 2′,7′-dichlorofluorescin diacetate, luminol, and lucigenin as indicators of reactive species formation Biochem. Pharmacol. 2003, 65, 1575-1582 (Pubitemid 36581871)
42. Ghose, A. K.; Crippen, G. M. Atomic physicochemical parameters for 3-dimensional-structure-directed quantitative structure-activity-relationships. 2. Modeling dispersive and hydrophobic interactions J. Chem. Inf. Comput. Sci. 1987, 27, 21-35
43. Sheldrick, G. M. A short history of SHELX Acta Crystallogr., Sect. A 2008, 64, 112-122
44. Farrugia, L. J. ORTEP-3 for windows-A version of ORTEP-III with a graphical user interface (GUI) J. Appl. Crystallogr. 1997, 30, 565 (Pubitemid 127791756)
45. Farrugia, L. J. WinGX suite for small-molecule single-crystal crystallography J. Appl. Crystallogr. 1999, 32, 837-838 (Pubitemid 129794704)
46. Richardson, D. R.; Milnes, K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents 0.2. The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone Blood 1997, 89, 3025-3038 (Pubitemid 27172591)
47. Baker, E.; Richardson, D.; Gross, S.; Ponka, P. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture Hepatology 1992, 15, 492-501
48. Becker, E.; Richardson, D. R. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-Pyridylcarboxaldehyde isonicotinoyl hydrazone analogs J. Lab. Clin. Med. 1999, 134, 510-521 (Pubitemid 29530701)
49. Richardson, D. R.; Baker, E. The uptake of iron and transferrin by the human-malignant melanoma cell Biochim. Biophys. Acta 1990, 1053, 1-12 (Pubitemid 20193885)
50. Richardson, D. R.; Baker, E. Intermediate steps in cellular iron uptake from transferrin-Detection of a cytoplasmic pool of iron, free of transferrin J. Biol. Chem. 1992, 267, 21384-21389
51. Dean, R. T.; Nicholson, P. The action of 9 chelators on iron-dependent radical damage Free Radical Res. 1994, 20, 83-101 (Pubitemid 24103739)